Scaling Smart: Leveraging Fractional C-Suite Talent in Early-Stage Biotech

Is it time to rethink how early-stage biotech builds its leadership?

As biotech funding models shift and development milestones grow more complex, many early-stage companies are rethinking how they build leadership. This report explores why 2025 may be the tipping point for fractional C-suite hiring—and how founders, investors, and hiring teams can use this model to scale smarter.

What you’ll learn in this report:

• When to hire fractional C-suite leaders – Six clear triggers that signal it’s time to bring in strategic leadership without a full-time commitment.
• What’s driving the shift – From cost pressures to hiring delays, discover the forces reshaping executive hiring in early-stage biotech.
• Cost comparison – See how fractional CMOs and CSOs stack up against full-time hires, with up to 40% cost savings.
• Key considerations and risks – Insights on how to make fractional leadership work—and what to watch out for.
• Real-world example – How Editas Medicine used interim leadership to bridge the gap from formation to funding.

Read the full report to stay ahead of the curve.